Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
4661 | 1675 | 25.9 | 56% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
2118 | 4652 | BINUCLEATED LYMPHOCYTES//HUMANIZED MICE//CHEMOSENSITIVITY TEST |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | CHEMOSENSITIVITY TEST | Author keyword | 33 | 57% | 2% | 39 |
2 | HISTOCULTURE DRUG RESPONSE ASSAY | Author keyword | 16 | 58% | 1% | 18 |
3 | CD DST | Author keyword | 12 | 75% | 1% | 9 |
4 | CHEMOSENSITIVITY TESTING | Author keyword | 8 | 45% | 1% | 14 |
5 | EXTREME DRUG RESISTANCE | Author keyword | 8 | 75% | 0% | 6 |
6 | ATP TCA | Author keyword | 8 | 100% | 0% | 5 |
7 | HISTOCULTURE | Author keyword | 7 | 43% | 1% | 13 |
8 | COLLAGEN GEL DROPLET EMBEDDED CULTURE DRUG SENSITIVITY TEST | Author keyword | 7 | 57% | 0% | 8 |
9 | ADJUVANT CANCER CHEMOTHERAPY | Author keyword | 6 | 80% | 0% | 4 |
10 | HISTOCULTURE DRUG RESPONSE ASSAY HDRA | Author keyword | 6 | 80% | 0% | 4 |
Web of Science journal categories |
Author Key Words |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | INVITRO CHEMOSENSITIVITY | 46 | 65% | 3% | 44 |
2 | 3 DIMENSIONAL HISTOCULTURE | 36 | 83% | 1% | 20 |
3 | MTT ASSAY | 28 | 28% | 5% | 85 |
4 | MTT END POINT | 23 | 76% | 1% | 16 |
5 | CHEMOSENSITIVITY ASSAY | 22 | 81% | 1% | 13 |
6 | IN VITRO CHEMOSENSITIVITY | 20 | 62% | 1% | 21 |
7 | INDIVIDUALIZED CHEMOTHERAPY | 18 | 83% | 1% | 10 |
8 | LUMINESCENCE ASSAY | 16 | 47% | 1% | 25 |
9 | COLONY FORMING ASSAY | 16 | 58% | 1% | 18 |
10 | STEM CELL ASSAY | 13 | 62% | 1% | 13 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer | 1999 | 67 | 30 | 67% |
In vitro assays for the evaluation of drug resistance in tumor cells | 2009 | 25 | 30 | 73% |
Chemotherapy sensitivity and resistance assays: A systematic review | 2004 | 70 | 15 | 73% |
INVITRO SENSITIVITY ASSAYS IN CANCER - A REVIEW, ANALYSIS, AND PROGNOSIS | 1991 | 65 | 106 | 84% |
TO DO TISSUE-CULTURE IN 2 OR 3 DIMENSIONS - THAT IS THE QUESTION | 1993 | 64 | 21 | 57% |
PREDICTION OF RESPONSE TO DRUG-THERAPY OF CANCER - A REVIEW OF INVITRO ASSAYS | 1992 | 81 | 51 | 59% |
The Microculture-Kinetic (MiCK) Assay: The Role of a Drug-Induced Apoptosis Assay in Drug Development and Clinical Care | 2012 | 2 | 9 | 67% |
Assay-based response evaluation in head and neck oncology: requirements for better decision making | 2010 | 10 | 69 | 41% |
Methods and goals for the use of in vitro and in vivo chemosensitivity testing | 2007 | 31 | 82 | 27% |
Prediction of individual response to anticancer therapy: historical and future perspectives | 2015 | 2 | 286 | 13% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | CHEMOSENSITIVITATESTUNGEN | 3 | 100% | 0.2% | 3 |
2 | MICHAEL DARMADY | 2 | 40% | 0.2% | 4 |
3 | CHEMOSENSIT TESTING | 1 | 50% | 0.1% | 2 |
4 | PEDIAT PULMONOL ALERGOL HEMATOL | 1 | 50% | 0.1% | 2 |
5 | SECT IBBENBUREN | 1 | 50% | 0.1% | 2 |
6 | SECT PATHOL 3 | 1 | 50% | 0.1% | 2 |
7 | PEDIAT HEMATOL CHEMOTHER Y | 1 | 20% | 0.2% | 4 |
8 | COALL STUDY GRP | 1 | 33% | 0.1% | 2 |
9 | PORTSMOUTH ONCOL | 1 | 33% | 0.1% | 2 |
10 | TOBU CHIIKI HOSP | 1 | 21% | 0.2% | 3 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000120692 | FP3//HOLLOW FIBRE ASSAY//AFFILIATED ZHUJI HOSP |
2 | 0.0000102395 | TRANSPLACENTAL MUTAGENICITY//ANTITUMOR PREPARATIONS//CANA3DTPA |
3 | 0.0000090171 | LEUKEMIC BLAST PROGENITORS//L CFU//500 SHERBOURNE ST |
4 | 0.0000074081 | BUCCAL DRUG ABSORPTION//HUMAN ENDOMETRIAL ADENOCARCINOMA//BIOL CHEM ERNAHRUNGSWISSEN AFT |
5 | 0.0000071321 | 2 3 4 DIARYL 5 OXO 1 2 4 TRIAZINE 6 YLIDENEACETATES//3 4 DIARYL 1 2 4 TRIAZOLO 5 CARBOXYLATES//ADEUOVIRUS |
6 | 0.0000066408 | PREDICTIVE ASSAYS//INDIVIDUAL RADIOSENSITIVITY//NORMAL TISSUE RESPONSE |
7 | 0.0000065461 | SMALL CELL LUNG CANCER CELL LINE//SMALL CELL LUNG CANCER CELL LINES//DRUG SCREENING ASSAY |
8 | 0.0000063510 | NBD GLUCOSAMINE//// |
9 | 0.0000058798 | TULAREMIA LIVE VACCINE//1 HEXYLCARBAMOYL 5 FLUOROURACIL//5 FLUOROURACIL AND 1 HEXYLCARBAMOYL 5 FLUOROURACIL |
10 | 0.0000046185 | PEPTICHEMIO//ALKYLATING PEPTIDES//HUMAN MYELOMA CELLS |